ctDNA sequencing analysis can identify potential BRCA1/2 reversal mutations in ovarian cancer patients (28), facilitating the screening of patients who are suitable for PARP inhibitor therapy (29, 30). This evidence concerns the gene BRCA1 and ovarian cancer.